Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BioSyent Pharma Signs Exclusive Licensing and Distribution Agreement For Two New Drug Products
MISSISSAUGA, ONTARIO--(Marketwire -08/16/12)- BioSyent Inc. ("BioSyent") (RX.V) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Licensing and Distribution Agreement with a European partner for two new products that will be marketed by its' Hospital Products Division. The products utilize a patented delivery system which will provide Canadian hospitals and healthcare professionals improved safety and cost effectiveness versus products currently in use. The products will be launched after Health Canada approval.
BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
Contact:
BioSyent Inc.
Rene C. Goehrum
President and CEO
(905) 206-0013
(905) 206-1413 (FAX)
www.biosyent.com
Note that they only sell in Canada so what is sold in the US is irrelevant.
BioSyent is misleading the public with recent announcement regarding their new oral iron powder for solution.
This is a false statement: FeraMAX(R) Powder is the only oral iron product available in a dissolvable powder and comes in pleasant tasting grape/raspberry flavoured - - there has been a product available in the states for the last two years, and by the looks of it BioSyent copied their formula. If you Google NovaFerrum you will see BioSyent even duplicated their combination of flavors Raspberry/Grape. BioSyent should be held accountable for misleading the public with misinformation.
The chart looks primed.
http://screencast.com/t/d44lCgNfxK
Yet another insider buy on BIOYF / RX.V. The latest was for 11,500 at $0.62.
Jul 3/12 Jun 29/12 D'Souza, Alfred Indirect Ownership Common Shares 10 - Acquisition in the public market 11,500 $0.620
BioSyent Pharma Secures Two Long-Term Hospital Supply Contracts for Cathejell(TM) Jelly 2%-Shipments Commence
TORONTO, ONTARIO--(Marketwire - June 19, 2012) - BioSyent Inc. ("BioSyent") (RX.V) today announced that its subsidiary BioSyent Pharma Inc. has secured two long-term hospital supply contracts for its recently launched Cathejell(TM) Jelly 2%.
One supply agreement is for a three year period, ending in June 2015 and the second agreement is for a four year period ending in June 2016. Shipments to supply both contracts have commenced. Total volumes under the two contracts are open ended and give Cathejell(TM) Jelly 2% access to hospitals and healthcare facilties representing approximately 2/3 of the Canadian market.
"We are pleased with the initial feedback from urologists and other health care professionals to the Cathejell(TM) Jelly 2% launch. They clearly see the benefits of our product relating to patient safety and ease of use", commented Rene Goehrum, President and CEO of BioSyent. "These contracts will provide a platform for us to build this brand in Canada for years to come".
Cathejell(TM) Jelly 2% is an innovative pharmaceutical product that combines a sterile gel and lidocaine in a unique collapsible applicator syringe which provides a safe and effective solution for healthcare professionals and patients to ease the discomfort of a range of medical procedures.
BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contact:
Rene C. Goehrum
BioSyent Inc.
President and CEO
www.biosyent.com
That was a great report all around. The extension of Feramax certainly sounds promising. We already know how profitable it is....
They have done a great job controlling expenses. With new reps, advertising Cathejell and the move to the new offices, I thought first quarter earnings were going to take a hit. My two cents is that this company is run by top notch management that has demonstrated it can do alot with a little.
I ve got alot of shares and am in for the long haul. Not alot of macro risk worry here with this.
There is one other nugget in the RX.V / BIOYF filing. They stated: "The Company also filed a new product which is a line extension to FeraMAX® with Health Canada and has added two new sales people during Q1."
I'm now increasing my 2012 EPS estimate for BIOYF / RX.V to C$0.12/share. That would be great for a stock that last traded at C$0.58.
There was another insider purchase at $0.588 posted a few weeks back:
http://canadianinsider.com/node/7?menu_tickersearch=RX+|+BioSyent
May 7/12 Apr 17/12 Montador, Paul Direct Ownership Common Shares 10 - Acquisition in the public market 10,000 $0.588
Their growth in pharmaceutical sales continued nicely this quarter. They now have 10 consecutive quarters of sequential growth in pharmaceutical sales. That is almost entirely from FeraMAX and we are now adding another product. Here is the history:
Quarter Pharma Revenue
Q1'12 $761,372
Q4'11 $657,442
Q3'11 $604,523
Q2'11 $465,163
Q1'11 $322,648
Q4'10 $247,941
Q3'10 $191,716
Q2'10 $155,024
Q1'10 $81,237
Q4'09 $78,392
Q3'09 $44,772
Agree, what's really impressive is those first quarter results are just from adding a few more salespeople to sell their current product, but don't reflect any of the growth that will come from the introduction of their new product, Cathjell, happening now......and with a larger sales force behind it from the beginning.
I maintain that this little company has what it takes to grow into a well known name.....and grow their stock value by multiples from it's current level.
That was an awesome report by RX.V / BIOYF. I backed up the truck this morning and purchased a lot more!
BioSyent Releases First Quarter Results-Sales Increase 89%, Net Income Sets All-Time Quarterly Record
TORONTO, ONTARIO--(Marketwire - May 22, 2012) - BioSyent Inc. ("BioSyent") ( RX.V - News) today released a summary of its First Quarter (Q1) 2012 financial results.
-- Operating Net Income sets all-time record for any quarter
-- Net Income increased from a loss of $886 in Q1 2011 to a profit of
$272,851 in Q1 2012
-- Q1 diluted earnings per share of $0.02
-- Q1 2012 Pharmaceutical Sales grow 136% vs. Q1 2011
Sales for Q1 2012 were 89% higher at $ 904,488 compared to $ 478,295 in the corresponding prior year period. The strong growth was driven by the pharmaceuticals business which grew by 136% from $322,648 in Q1 2011 to $ 761,372 in Q1 2012.
The Company earned total comprehensive (net) income of $272,851 in Q1 2012 compared to a total comprehensive loss of ($886) in Q1 2011. The Company has utilized losses carried forward from prior years and therefore has no tax provision for Q1 2012.
During the quarter Working Capital increased by 24% from $1,128,065 as at December 31, 2011 to $1,394,641 on March 31, 2012. Cash and cash equivalents as at March 31, 2012 were $1,059,036. The Company continues to be free of long term debt, and has not utilized any of its bank facilities to fund the continued strong increase in sales. During the First Quarter the Company channelled most of the incremental cash flow resulting from Net Income into investments in non-cash working capital, primarily inventory.
Shares issued and outstanding as of quarter end March 31, 2012 were 12,791,195.
The Financial Statements and Management's Discussion & Analysis will be posted on sedar.com on May 22, 2012.
BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contact:
Rene C. Goehrum
BioSyent Inc.
President and CEO
www.biosyent.com
This is one company product I have no wish to try out myself!
Cathejell looks like a solid addition to this little company's portfolio. It looks like it can be used for just about any kind of noninvasive procedure, but seams to be targeted to catheterization and endoscopic markets, which those alone have to be fairly large addressable markets:
http://www.cathejell.ca/information.html
Cathjell looks to be a pretty important product to it's manufacturer Montavit, a privately owned Austrian company, they license it worldwide to some multi-billion dollar companies like NYSE - TFX:
http://www.montavit.com/index_eng.html
....it actually looks like TFX has it as a private label w/o Lidocaine and calls it Trachgell:
http://www.teleflex.com/commonInternet/emea/documentLibrary/viewDocument/emea/163/en/940616-000001_TracJell_1109.pdf#search='lidocaine'
Biosyent's product website for Cathjell looks top rate: http://www.cathejell.ca/index.html
Cathjell has it's own Youtube videos (CAUTION: Viewing may cause discomfort and uncontrollable cringing):
BioSyent Pharma Launches Cathejell(TM) Jelly 2%; Shipments to Commence May 2012
TORONTO, ONTARIO--(Marketwire -05/09/12)- BioSyent Inc. ("BioSyent") (TSX-V: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has launched Cathejell™ Jelly 2% a Sterile Topical Anesthetic for the Canadian healthcare market.
Cathejell™ Jelly 2% is an innovative pharmaceutical product that combines a sterile gel and lidocaine in a unique collapsible applicator syringe which provides a safe and effective solution for patients to ease the discomfort of a range of medical procedures. Cathejell™ Jelly 2% is indicated for surface anesthesia and lubrication for various procedures including: male and female cystoscopies, catheterizations and other endourethral operations; endoscopies, proctoscopies, rectoscopies; and tracheal intubations. Cathejell™ Jelly 2% can also be used for the symptomatic treatment of pain in connection with cystitis and urethritis.
Cathejell™ Jelly 2% was in-licensed by BioSyent Pharma from Pharmazeutische Fabrik MONTAVIT of Absam, Austria (MONTAVIT) and was approved by Health Canada in July 2011 (DIN 02370840). MONTAVIT has been producing and successfully marketing Cathejell™ Jelly 2% for over 40 years. Cathejell™ Jelly 2% is used by healthcare professionals in hospitals and clinics in over 50 countries around the world including England, Germany, France, Switzerland, Sweden, Italy and Spain.
Cathejell™ Jelly 2% has a unique collapsible syringe design with a trauma-free applicator tip that makes it easy to use for healthcare professionals and makes the application of the drug more comfortable for the subject patient.
Cathejell™ Jelly 2% is now available to all hospitals, pharmacies and urology clincs across Canada. Shipments for Cathejell™ Jelly 2% will commence in May 2012. For more information regarding Cathejell™ Jelly 2% visit www.cathejell.ca.
BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contact:
BioSyent Inc.
Rene C. Goehrum
President and CEO
www.biosyent.com
Typo....It should have been "November of 2010" instead of 2003.
Excellent post. RX.V / BIOYF sees $1+ this year IMO and with any luck $2.00
I have a few comments on that.
1. They trumpeted their compound growth rate in the last PR. I don't think they would say that if it growth was about to dramatically slow.
2. One quarter does not make a trend. There has been significant variation in the sequential dollar growth and percentage growth so you have to look longer term. See the table below. In November of 2003 would you have concluded that growth was slowing based upon the results of Q3'10?
Sequential Growth
Dollars Percentage
Q4'11 $52,919 8.8%
Q3'11 $139,360 29.9%
Q2'11 $142,525 44.2%
Q1'11 $74,707 30.1%
Q4'10 $56,225 29.3%
Q3'10 $36,692 23.7%
Q2'10 $73,787 90.8%
Q1'10 $2,845 3.6%
Q4'09 $33,620 75.1%
Well the growth is slowing. That's all really. Do you have another view? I'd love to think theres some more growth left for it, but who knows, people have probably become pretty much aware of it by now.
Why do you think Feramax will level off in revenue at $3M? I haven't seen any data to support that.
It sounds like the insecticide business was off for natural reasons - bug infestations were low or something like that.
Still the results were a little disapointing to me. I would now guess Feramax levels off around 3mm in revenues. I had been optimistic it could be a 4mm product. Theres a big difference there when you ve got 80% gross margins.
It would have been nice to read more about the pipeline of new products. The new analgesic is supposed to start shipping in the first half so maybe we ll see some results from it this year.
Obviously the compnany is planning for some serious growth. Did you see they have just moved into a new facilty? I bet it's big, bump in rent expense is significant.
IMO you are interpreting that data incorrectly. Insecticide sales were $217,250 in Q4'10 and $45,895 in Q4'11. If insecticide sales in Q4'11 were the same as those in Q4'10 they would have made roughly $0.01/share more and Q4'11 EPS would have been more than double that of 2010. I don't think they have much variable overhead costs for the insecticide business because they aren't marketing it heavily and are basically maintaining the business. If they did segment reporting they would probably show a significant loss in the insecticide business for Q4'11 for that segment. I'm sure the pharmaceutical sales segment made more money in Q4'11 than it did in Q4'10 by a long shot.
Keep in mind that the insecticide business is very seasonal and lumpy. In Q4'09 they only had $39,967 in insecticide sales. After that poor Q4'09 they went on to have a great 2010. I think the insecticide product is a good business for them but it generally isn't growing and the results do fluctuate especially on a quarterly basis.
Just read through the 10k, and the main reason why the earning during the 4th quarter fell 19% despite 51% revenue rise vs. a year ago was because of higher total expenses which were $638,117 in 4q 2011 compared to $384,818 in 4q 2010.
BioSyent Releases Fiscal 2011 and Fourth Quarter Financial Results-Strong Growth Continues
TORONTO, ONTARIO--(Marketwire -03/29/12)- BioSyent Inc. ("BioSyent") (TSX-V: RX.V - News) today released a summary of its Fiscal 2011 and Fourth Quarter (Q4) 2011 financial results.
-- 2011 Q4 Sales increased 51% vs Q4 2010
-- 2011 Full Year Sales increased 67% vs 2010
-- 2011 Pharma Sales increased 203% following a 201% increase in 2010
-- Pharma compound quarterly growth rate of 35% over last 8 quarters
-- 2011 Full Year Profit increased 8.6 times over 2010
Total Sales for Q4 2011, hit a new record and were 51% higher at $703,337 in Q4 of 2011, compared to $465,191 in the corresponding prior year period. Sales for full year 2011 were 67% higher at $2,808,666 compared to $1,681,210 in the prior year period. The growth was driven by the pharmaceutical business which grew by 203% from $675,918 in 2010 to $2,049,776 in 2011.
The Company earned total comprehensive income of $417,950 for Full Year 2011, which was 8.6 times the total comprehensive income in 2010 of $48,386. The Increase in Cash and Cash Equivalents of $586,950 for Fiscal Year 2011, was 14.6 times the corresponding figure of $40,307 in the prior year period. Working Capital increased by 75% from $642,811 on December 31, 2010 to $1,128,065 at the end of 2011.
The Financial Statements and Management's Discussion & Analysis will be posted on sedar.com on March 29, 2011.
BioSyent Inc. also announces the grant of 100,000 incentive stock options to an employee of the Company. These incentive stock options are exercisable at a price of $0.57 up to March 28, 2017.
BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to, it.
BioSyent Inc. is a publicly traded specialty pharmaceutical company whose wholly owned subsidiary, BioSyent Pharma Inc., sources, acquires or in-licences pharmaceutical products and markets these products in Canada. Wholly owned BioSyent subsidiary Hedley Technologies Ltd. operates the company's legacy business marketing bio and health friendly non-chemical insecticides. BioSyent common shares are listed for trading on the TSX Venture Exchange (TSXV) under the symbol RX.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Contact:
BioSyent Inc.
Rene C. Goehrum
President and CEO
www.biosyent.com
The growth in pharmaceutical sales has varied significantly from quarter to quarter when you look at it on an absolute dollar basis. On an absolute dollar basis the growth in Q3'11 sales was the largest ever at $139K so it isn't surprising that the growth rate slowed down a bit in Q4 as the growth rate was probably temporarily higher.
You're smart and right, thanks. Still, the slowdown of the pharmaceutical sales growth, and earning during the 4th quarter falling year over year are not encouraging.
I calculated the Q4 pharmaceutical sales. They said 2011 pharmaceutical sales increased by 203%. So, I took 2010 pharmaceutical sales, multiplied them by 3.03 and subtracted pharmaceutical sales for the first 9 months.
Where did you get the number of $656k as Pharmaceutical sales? I could not find it, and worry that pharmaceutical sales durinng the 4th quarter might fall sequentially as well. Hope it did not.
Expected. You don't sell as much bug spray under 12 feet of snow as you do under 100 degree heat. YOY numbers more relevant as well as pharmaceutical numbers which were up sequentially.
According to my calculations, BioSyent had a 9th consecutive quarter of sequentially increasing pharmaceutical sales. Pharmaceutical sales were roughly $656K. Insecticide sales were only roughly $47K. Q4 is the seasonally slow period for insecticide sales and this year Q4 insecticide sales came in lighter like they did in 2009.
My estimate for 2012 is for diluted EPS of $0.10/share.
Seems that its 4th quarter revenue and profit fell sequentially, and earning per shares during the 4th quarter of 2011 was about $0.005.
It trades on the Toronto Stock Exchange. To buy it in the USA, you enter BIOYF and it is routed to the TSX. It doesn't need MMs because your buys and sells go there automatically.
How do you purchase shares of this security? It looks like it's listed on the grey market meaning there are no market makers in this issue.
??? "It just can't be posted" are you saying we should not post DD???
Maybe I missed the post -- how do you calculate $3.50 target?
I personally don't have an exact target yet.
At $3.50 will it make a difference..
BTW I'd really like to see indepth DD that confirms mine as to why it will trade at $3.50.. It just can't be posted or talked up..
I must of missed something in this one of your latest posts.. hank
Higher than 14 year highs? I could have been wrong. Used Yahoo interactive charts to try to figure it out and haven't seen prices higher since 1998.
Which I guess could mean 13 year highs instead of 14. Hmmm.
BIOYF.. Looks higher to me..
02/24/12 1:05 PM EST Buy 6000 BIOYF Executed @ $0.637 Details | Edit
02/24/12 11:43 AM EST Buy 1000 BIOYF Executed @ $0.637 Details | Edit
02/23/12 2:58 PM EST Buy 2000 BIOYF Executed @ $0.686 Details | Edit
02/23/12 2:58 PM EST Buy 388 BIOYF Executed @ $0.686 Details | Edit
02/23/12 2:58 PM EST Buy 1000 BIOYF Executed @ $0.686 Details | Edit
02/23/12 2:58 PM EST Buy 3500 BIOYF Executed @ $0.686 Details | Edit
02/23/12 2:57 PM EST Buy 2000 BIOYF Executed @ $0.677 Details | Edit
02/23/12 10:57 AM EST Buy 12500 BIOYF Executed @ $0.678 Details | Edit
Nice DD. Friend mentioned this one
Do you know the name of the same product that is marketed in the US? Is the product doing as well there?
Your welcome lol
Now, answer?
So far the stock price move up has acted as the perfect stool softener for me....
What is the name of the product distributed in the US. Not arguing with success. Just trying to understand if Feramax is mostly selling itself or does the marketing approach account for the success in the otc market with many choices, including one that has a stool softener.
RX.V / BIOYF has a market cap under $10 million and is nicely proftiable and growing fast.....
They don't have to expand very much to deserve multiples in stock price reward. Heck, we should be double the price we are right now already and seem to be heading there IMO.
It is the ticker for Paladin Labs Inc. (PLB)
Exchange: Toronto Stock Exchange
The company Zen was saying Biosyent is modeled on. (to what degree I don't know)
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
166
|
Created
|
08/30/11
|
Type
|
Free
|
Moderators |
Stock Symbol: RX
Exchange: TSX Venture
Shares Outstanding: 12,521,195 (as of 8/24/2011)
Fully diluted: 14,315,825 (as of 12/31/2010)
BioSyent Inc. is a publicly traded life science company that acquires or licenses products and commercializes proprietary science-based technologies that advance human health and public safety (TSX Venture Exchange trading symbol - "RX").
BioSyent has embarked on a growth strategy to establish itself in Canada's pharmaceutical industry. BioSyent's focus is: sourcing pharmaceutical products that have been successfully developed and proven safe and effective; managing the regulatory process through to product registration (approval); and once approved, marketing these products in Canada. The Company is focused on medications that occupy a niche in the market, that are unique either due to complexity of manufacture or provide novel technological or therapeutic advantages, or that are backed by strong partners holding intellectual property rights that are defendable. This strategy allows the Company to market these medications as brands owned by, or licensed to it.
In keeping with the above strategy, the Company has, through its subsidiary, BioSyent Pharma Inc. launched FeraMAX®, an oral hematinic, to the Canadian healthcare market. FeraMAX® is indicated for the prevention and treatment of iron deficiency anaemia (IDA). This non-ionic formulation leads to improved iron absorption by the body and eliminates adverse side effects normally associated with iron formulations. Shipments of FeraMAX® commenced in April 2007.
In 2008 BioSyent Pharma Inc. established a Hospital Products Division focused on licensing or acquiring pharmaceutical products used primarily in a hospital setting. The Hospital Products Division licensed its first product, Ciprofloxacin Injection, in the first quarter of 2008 and launched the product in the second quarter of 2008. Ciprofloxacin Injection, an antibacterial agent, is a generic equivalent to Cipro I.V. Minibags 2mg/ml from Bayer Inc.
In July 2009, the company through its subsidiary BioSyent Pharma Inc. signed an exclusive distribution agreement with a partner for an innovative topical anaesthetic product used in urology and gastroenterology. The product was approved by Health Canada in July, 2011.
The Company also manufactures and markets two products from its legacy business, namely Protect-It® and Insecolo™.
Protect-It® is a non-chemical, food-safe grain insecticide. The patented formula contains a natural mineral called diatomaceous earth ("DE"). Protect-It® was developed through collaborative research between the Winnipeg based Cereal Research Centre of Agriculture and Agri-Food Canada. Protect-It® is used as a preventative treatment against insect infestations in stored grains. It is registered for use in Canada, the United States, Croatia and Syria.
Insecolo is a natural insecticide for home and garden use made from a patented formula of DE and food grade additives. It is registered for use in Canada and is marketed by S.C. Johnson and Son Limited under the Raid® Earthblends™ Ant & Earwig Dust brand.
http://www.bugsmart.ca/alternative/26.aspx
Management Profiles:
René C. Goehrum, Chairman, President, Chief Executive Officer
René Goehrum is an experienced entrepreneur, leader and business builder. He has led businesses and teams at various stages of their development including start-ups, growth companies and mature products/businesses. His focus is on strategy, corporate and business development, and operations. Mr. Goehrum's career experience includes: Chariman, President and Chief Executive Officer of BioSyent Inc. (f.k.a. Hedley Technologies Inc.), a publicly Traded (TSXV-RX) specialty pharmaceutical company. President and co-founder of Bratch Goehrum Inc., a professional services firm that provided marketing and sales services to clients such as Procter & Gamble, Boehringer Ingelheim, Sandoz (n.k.a. Novartis), Kraft Foods, Coca Cola, H.J. Heinz Company and Canadian Imperial Bank of Commerce (CIBC). Progressive sales and product promotion assignments with Procter & Gamble Inc., a world leader in the development and marketing of consumer products. Mr. Goehrum's functional experience includes corporate strategy, sales and marketing strategy and execution, business operations and corporate finance.
Alfred D'Souza, Chief Financial Officer, Vice President Biosyent Inc.
Alfred D'Souza has been the Chief Financial Officer and Vice President of BioSyent Inc. since December 13, 2007. Mr. D'Souza joined BioSyent as Controller and Director of Finance in October 2006. Mr. D'Souza has over 25 years of accounting, finance and operations management experience in international businesses ranging from early stage to rapid growth to mature markets. Mr. D'Souza enjoyed a 16 year career with progressive management assignments at Colgate-Palmolive ... Company. Mr. D'Souza's last two positions at Colgate-Palmolive were Head of Finance (Country Controller) at Colgate-Palmolive Vietnam while it grew from sales of less than to USD $2 million to over $25 million, and most recently as Finance Director and Controller of Colgate-Palmolive India a publicly traded (BSE) USD $225 million company with 4,000 employees and 6 manufacturing plants in India. Mr. D'Souza is a Certified Management Accountant and M.B.A. from Wilfrid Laurier University.
Douglas R. Larson, Director
Douglas R. Larson has considerable grain industry experience. Before August 1995, he served as President and CEO of James Richardson and Sons Ltd.-Grain Division. James Richardson and Sons is Canada's largest privately owned grain company. During the past forty years, Mr. Larson has served the grain industry in many capacities, including: President of Vancouver Grain Exchange; President of B.C. Terminal Elevators Operators' Association; a Director of the Canada Grains Council; Member of the Grain Elevators and Processors Society; Chairman of the Board of the Chamber of Maritime Commerce; a Member of the Board of Directors of Grain Insurance and Guarantee Company; Member of the Labour Canada Working Group for the Western Grain Elevator Industry; Member, Implementation Advisory Team, Agriculture Canada Grain and Oilseeds Branch.
Peter D. Lockhard, Director
Peter Lockhard is an entrepreneur and business leader with senior management, operations, sales/sales management, marketing and client service experience in the technology and marketing services industries. Mr. Lockhard, is a co-founder and principal of Aquiam Partners Ltd., a private corporation engaged in investment, acquisition, management and growth of entrepreneurial enterprises. After starting his career in public accounting and investment sales, Mr. Lockhard co-founded and served as President (1990-1998), of Between the I's a technology-based marketing services provider with clients such as Pepsi-Cola Canada, Bell Canada, Nortel and Labatt Breweries. Prior to founding Aquiam Partners, Mr. Lockhard served as a senior executive in several technology based businesses that served large multi-national clients such as Hewlett-Packard, Microsoft, Bank of Montreal, Barnes and Noble and American Airlines.
Milton E. Wakefield, Director
Milton Wakefield recently completed a ten-year term as Commissioner of the Canadian Grain Commission, the last seven as its Chief Commissioner. The Canadian Grain Commission is the regulatory agency responsible for maintaining grain quality standards and assessment in Canada. As its Chief Commissioner, Mr. Wakefield was responsible for advising the Minister of Agriculture on grain industry policies and regulations, and carrying the principal responsibility for promoting Canadian grain quality standards and management practices internationally. Mr. Wakefield has chaired several industry committees including the Western and Eastern Grain Standards Committees and was responsible for supervising the Winnipeg Commodity Exchange. During his tenure, Mr. Wakefield led several grain industry missions to Japan, the People's Republic of China, and several countries in South East Asia and Europe.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |